Search research articles
Contact Us
Filters
Showing results (21-30 of 45) with videos related to
Page
of 5
Sort By:
Journal of Clinical Medicine
|
December 2, 2020
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 17, 2019
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project
Michèle Beau-Faller, Erwan Pencreach, Charlotte Leduc, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 13, 2017
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
Nicolas Guibert, Fabrice Barlesi, Renaud Descourt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2025
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS
Elisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Journal for Immunotherapy of Cancer
|
October 21, 2022
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
Marie Wislez, Julien Mazieres, Armelle Lavole, et al.
Oncotarget
|
December 24, 2016
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial
Guénaëlle Levallet, Fatéméh Dubois, Pierre Fouret, et al.
The European Respiratory Journal
|
August 12, 2017
EGFR tyrosine kinase inhibitors <i>versus</i> chemotherapy in <i>EGFR</i> wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Pascale Tomasini, Solenn Brosseau, Julien Mazières, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2025
Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS"
Elisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Bulletin Du Cancer
|
July 10, 2017
[Clinical research activity of the French cancer cooperative network: Overview and perspectives]
Claire Dubois, Franck Morin, Denis Moro-Sibilot, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 20, 2022
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial
Pierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 45) with videos related to
Sort By:
Page
of 5
Journal of Clinical Medicine
|
December 2, 2020
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 17, 2019
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project
Michèle Beau-Faller, Erwan Pencreach, Charlotte Leduc, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 13, 2017
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
Nicolas Guibert, Fabrice Barlesi, Renaud Descourt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2025
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS
Elisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Journal for Immunotherapy of Cancer
|
October 21, 2022
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
Marie Wislez, Julien Mazieres, Armelle Lavole, et al.
Oncotarget
|
December 24, 2016
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial
Guénaëlle Levallet, Fatéméh Dubois, Pierre Fouret, et al.
The European Respiratory Journal
|
August 12, 2017
EGFR tyrosine kinase inhibitors <i>versus</i> chemotherapy in <i>EGFR</i> wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Pascale Tomasini, Solenn Brosseau, Julien Mazières, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2025
Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS"
Elisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Bulletin Du Cancer
|
July 10, 2017
[Clinical research activity of the French cancer cooperative network: Overview and perspectives]
Claire Dubois, Franck Morin, Denis Moro-Sibilot, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 20, 2022
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial
Pierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, et al.
Page
of 5